NCT01083758

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Effect of Calcipotriol Plus Betamethasone Dipropionate Topical Suspension on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 17 Years) With Scalp Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 topical suspension in adolescent subjects (aged 12 to 17 years) with scalp psoriasis. LEO 80185 topical suspension has marketing approval in many countries under the brand names Taclonex Scalp® Topical Suspension and Xamiol® gel for the treatment of scalp psoriasis in adults. No studies have been performed in subjects younger than 18 years.

Conditions

• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)	Topical suspension applied once daily for up to 8 weeks

Timeline

• Start date: 2010-04-01
• Primary completion: 2012-08-01
• Completion: 2012-10-01
• First posted: 2010-03-10
• Last updated: 2025-03-11
• Results posted: 2015-10-12

Locations

6 sites across 1 country: United States